Join to view full profile
55 Fruit StBoston, MA 02114
Phone+1 617-724-4000
Dr. Farago is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2014- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2010
Harvard Medical SchoolClass of 2008
Certifications & Licensure
MA State Medical License 2010 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2016
Clinical Trials
- Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Start of enrollment: 2015 Oct 13
- Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Publications & Presentations
PubMed
- 4 citationsDefining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.Lang Ho Lee, Xin Xu, Thanos Mourikis, Fanying Tang, Lauren Fairchild
Cancer Research Communications. 2025-06-01 - 4 citationsA phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors.Susan C Scott, Anna Farago, W Victoria Lai, Marianna Zahurak, Michelle A Rudek
Cancer Chemotherapy and Pharmacology. 2025-02-25 - 8 citationsPhase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.Catherine B Meador, Subba R Digumarthy, Beow Y Yeap, Yin P Hung, Mari Mino-Kenudson
Clinical Cancer Research. 2025-01-06
Lectures
- Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Combining Forces in Small Cell Lung CancerNovember 21st, 2019
Potential New Treatment Strategy for Relapsed SCLCSeptember 11th, 2019
PARP Inhibitor Combination Shows Activity in Small Cell Lung CancerAugust 21st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: